Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review.

J Yeungnam Med Sci · 2026 · PMC12962768 · PMID 41645627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A favorable trend toward improved OS was seen in the SG plus pembrolizumab group, with an HR of 0.89 (95% CI, 0.62–1.29), although statistical significance was not reached [ 54 ].

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.